SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank83
5Y CAGR-15.6%
Studio
Year-over-Year Change

Year-over-year net income growth rate

5Y CAGR
-15.6%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
2025138.92%
202419.17%
2023-125.14%
2022-9.31%
2021-185.22%
2020323.88%
20190.00%